ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231	ANDA	Breckenridge Pharmaceutical, Inc.	51991-074-01	100 CAPSULE in 1 BOTTLE, PLASTIC (51991-074-01)	2009-05-01
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231	ANDA	Breckenridge Pharmaceutical, Inc.	51991-074-05	500 CAPSULE in 1 BOTTLE, PLASTIC (51991-074-05)	2009-05-01
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231	ANDA	Bryant Ranch Prepack	63629-2952-1	30 CAPSULE in 1 BOTTLE (63629-2952-1)	2009-05-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes key global suppliers of Active Pharmaceutical Ingredients (APIs) for Aspirin, Butalbital, Caffeine, and Codeine Phosphate. It identifies primary manufacturers, their production capacities, regulatory compliance, and market presence to inform R&D and investment strategies for pharmaceutical companies.

Who are the primary global manufacturers of Aspirin API?

Aspirin (acetylsalicylic acid) is a widely produced API with a mature market. Major manufacturers are concentrated in Asia, particularly China and India, benefiting from cost efficiencies and large-scale production capabilities. Key players include:

Bayer AG: While historically a dominant force and patent holder, Bayer now operates primarily as a major downstream formulator and marketer of aspirin-containing products. Its API manufacturing is integrated within its global operations, but it also sources extensively from third-party suppliers.
Lanxess AG: This German specialty chemical company has a significant presence in the production of acetylsalicylic acid, operating large-scale facilities. They are a key supplier for various pharmaceutical and industrial applications.
Sumitomo Chemical Co., Ltd.: A Japanese diversified chemical company with a strong presence in pharmaceutical intermediates and APIs, including aspirin.
Jubilant Life Sciences (now Jubilant Pharmova Limited): An Indian pharmaceutical and life sciences company that is a substantial producer of acetylsalicylic acid, serving both domestic and international markets. Their large-scale manufacturing capacity is a significant factor in global supply.
Anqiu Lonxin Pharmaceutical Co., Ltd.: A Chinese manufacturer specializing in APIs, including a significant output of aspirin. Chinese manufacturers are critical to the global supply chain due to their volume and competitive pricing.
Jiangsu Xinhua Pharmaceutical Co., Ltd.: Another major Chinese API producer with substantial capacity for aspirin production.

Production Scale and Market Dynamics: The global demand for aspirin API is in the tens of thousands of metric tons annually. Production is characterized by high-volume, low-margin operations. Manufacturers often achieve economies of scale through dedicated, continuous production lines. Regulatory adherence to Good Manufacturing Practices (GMP) and pharmacopoeial standards (USP, EP, JP) is universal for API suppliers.

What are the significant global sources for Butalbital API?

Butalbital is a barbiturate used in combination products for pain relief, particularly tension headaches. Its production is more specialized and consolidated than aspirin, with fewer primary manufacturers.

Sanofi S.A.: While Sanofi is a major pharmaceutical company that markets butalbital-containing products, its direct API manufacturing capacity for butalbital is not publicly detailed as a standalone focus. They are a significant purchaser of butalbital API.
Mallinckrodt Pharmaceuticals: A global biopharmaceutical company with a history of producing controlled substances and APIs, including butalbital. Their operations are subject to strict regulatory oversight due to the nature of the substance.
Siegfried AG: A Swiss company specializing in pharmaceutical contract development and manufacturing (CDMO). Siegfried produces a range of APIs, and butalbital is within their technical capabilities, though not always their primary advertised product.
Various Indian and Chinese Manufacturers: Several API manufacturers in India and China are registered to produce butalbital, often serving as contract manufacturers or supplying to global generic drug producers. Specific company names for large-scale, dedicated butalbital production are less publicly prominent than for more commoditized APIs. Examples of companies that have supplied butalbital include Taj Pharmaceuticals Limited (India) and some specialized chemical manufacturers in China.

Regulatory Landscape: Butalbital is a controlled substance in many jurisdictions. Manufacturers must adhere to stringent national and international regulations regarding production, handling, and distribution, including quotas and security measures. This regulatory burden influences market entry and competitive dynamics.

Which companies are major suppliers of Caffeine API?

Caffeine API is widely used not only in pharmaceuticals but also in food and beverage industries. This broad demand supports a large and diversified supplier base, with significant production in Asia and Europe.

Nestlé S.A.: While primarily a food and beverage company, Nestlé is a major producer and consumer of caffeine. They have internal manufacturing capabilities and also source significantly. Their focus is on high-purity, food-grade caffeine, which often meets pharmaceutical standards.
BASF SE: The German chemical giant is a significant producer of synthetic caffeine. BASF operates large-scale facilities and supplies caffeine to pharmaceutical, food, and beverage sectors globally. Their product is known for high purity and consistent quality.
Sino-Japanese Chemical Co., Ltd. (Japan): A prominent Japanese manufacturer of pharmaceutical raw materials, including caffeine.
Shanghai Pharma (China): A large pharmaceutical group in China involved in API manufacturing, including caffeine. Chinese suppliers are a substantial part of the global volume.
Kingchem Life Science LLC: A US-based company with manufacturing facilities in China, producing a range of APIs and intermediates, including caffeine.
Other Asian Manufacturers (China, India, Indonesia): Numerous smaller and medium-sized manufacturers in these regions contribute significantly to global caffeine supply, particularly for cost-sensitive markets.

Market Characteristics: The caffeine API market is characterized by significant volume driven by its dual use. Competition is intense, with price and quality being key differentiators. GMP certification and compliance with pharmacopoeial monographs are essential for pharmaceutical-grade caffeine.

Who are the principal global sources of Codeine Phosphate API?

Codeine phosphate is an opioid analgesic, and its production is highly regulated due to its controlled substance status and its derivation from opium alkaloids. Supply chains are tightly monitored.

Tasmanian Alkaloids Pty. Ltd. (Australia): A subsidiary of Johnson & Johnson, this is one of the world's largest legal producers of concentrated poppy straw, the raw material for opiate alkaloids including codeine. They process this into bulk opiates, including codeine, which is then further processed into codeine phosphate.
New Zealand Pharmaceuticals Ltd. (NZP): Another major Australian/New Zealand-based producer of opiate alkaloids and their derivatives. NZP is a significant supplier of codeine phosphate API to the global pharmaceutical market.
Opiant Pharmaceuticals (now part of Indivior PLC): While Indivior focuses on addiction treatments, Opiant has historically been involved in controlled substance APIs. Their role in direct codeine phosphate manufacturing is often as a specialized producer or through acquisitions.
Johnson & Johnson (Janssen Pharmaceutical Companies): Through its subsidiaries like Tasmanian Alkaloids, J&J is a foundational player in the supply of codeine-based APIs.
AARTI Industries Limited (India): A leading Indian manufacturer of specialty chemicals and pharmaceuticals. Aarti Industries is a significant producer of codeine phosphate, serving both the Indian and export markets, operating under strict regulatory frameworks.
Opium Poppy Cultivators and Processors in Other Countries: While Australia and Tasmania are dominant, other countries with legal opium cultivation (e.g., India under government control) also have processors that contribute to the global supply of alkaloid raw materials.

Regulatory Framework: The production and trade of codeine phosphate are subject to strict international control under the United Nations Single Convention on Narcotic Drugs, 1961. Manufacturers must possess licenses, adhere to production quotas set by national governments and the International Narcotics Control Board (INCB), and maintain rigorous security and tracking systems. This makes the market less accessible to new entrants and more consolidated among established, licensed entities.

Key Takeaways

Geographic Concentration: API production for Aspirin, Butalbital, Caffeine, and Codeine Phosphate shows varying degrees of geographic concentration, with Asia (China, India) being dominant for high-volume, less-regulated APIs like Aspirin and Caffeine. Butalbital has a more consolidated, specialized manufacturing base, while Codeine Phosphate production is heavily concentrated in regions with legal opium cultivation and strict international oversight (Australia, New Zealand, India).
Regulatory Influence: Controlled substances like Butalbital and Codeine Phosphate face significant regulatory hurdles, including international quotas and stringent handling requirements. This limits the number of manufacturers and increases compliance costs, impacting supply chain stability and pricing.
Market Maturity: Aspirin API operates in a mature, high-volume, low-margin market dominated by cost efficiencies. Caffeine API is also high-volume but benefits from dual pharmaceutical and food/beverage demand. Butalbital and Codeine Phosphate are niche markets with higher barriers to entry.
Supply Chain Risk: Companies relying on these APIs must conduct thorough due diligence on suppliers' regulatory compliance, production capacity, quality management systems, and geopolitical stability of their operating regions. Diversification of suppliers, especially for controlled substances, is a critical risk mitigation strategy.

Frequently Asked Questions

1. What are the main pharmacopoeial standards required for these APIs?

Suppliers must meet the standards outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). Specific monographs for Aspirin, Butalbital, Caffeine, and Codeine Phosphate detail identity, purity, assay, and impurity limits.

2. How does the controlled substance status of Butalbital and Codeine Phosphate affect their supply chain?

The controlled substance status necessitates strict licensing, quota adherence, secure handling, and detailed record-keeping from raw material sourcing to final API dispatch. This increases operational complexity, compliance costs, and can limit the number of qualified global suppliers.

3. Are there significant differences in quality between synthetic and naturally derived caffeine API?

Both synthetic and naturally derived caffeine can meet pharmaceutical standards. The key differentiator is the purity and consistency achieved through the manufacturing process and quality control. Reputable manufacturers, regardless of source, will ensure compliance with pharmacopoeial requirements.

4. What is the typical lead time for bulk API orders of these substances?

Lead times can vary significantly based on the API, supplier's current inventory, production schedule, and order volume. For commodity APIs like Aspirin, lead times might range from a few weeks to two months. For controlled substances like Codeine Phosphate, or specialized APIs with limited production runs, lead times can extend to three to six months or longer, depending on manufacturing slot availability and regulatory processing.

5. What is the impact of raw material availability on the supply of these APIs?

The availability and cost of key raw materials directly influence API supply. For Aspirin, acetic anhydride and phenol are critical. For Caffeine, urea and cyanoacetic acid are common precursors for synthetic production. For Codeine Phosphate, the availability of opium poppy straw from licensed cultivation is the primary constraint, dictating the supply of opiate alkaloids. Fluctuations in these raw material markets can create price volatility and supply disruptions.

Suppliers and packagers for generic pharmaceutical drug: ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE